Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un Nuevo Método para Compartir Planes de Radioterapia Entre Médicos, Ensayo CORRECT (CORRECT)

22 de octubre de 2026 actualizado por: Wake Forest University Health Sciences

Colaboración Oncológica entre Radiólogos y Oncólogos Radioterápicos para la Evaluación de Objetivos Delineados (CORRECT)

This clinical trial tests a new way to share radiation therapy plans using the Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) workflow to improve communication and collaboration between radiation oncologists (ROs) and radiologists when determining cancer targets for radiation treatment. Systemic barriers limit critical communication between radiation oncologists and radiologists and can lead to both under and overdosing of radiation therapy (RT) tumor targets and failures to properly interpret post-treatment imaging. The limited formal diagnostic radiology training of many providers can make differentiating normal from disease imaging findings during target determination difficult, especially in complex disease sites like the lung, head, and neck. Inaccurate target determination may result in cancer return, excess toxicity, or both. Likewise, radiologists who cannot access prior RT plans may mistake expected RT changes for recurrent cancer or overlook true progression. The CORRECT workflow was developed by ROs and radiologists to address RO-radiology communication barriers by facilitating sharing of comprehensive RT target contours during RT planning. The CORRECT workflow begins with the normal process of RO target contouring. Computed tomography (CT) images are then fused with RT targets and pushed to a pre-designated Picture Archiving and Communications System (PACS) software folder accessible by the radiology department. The radiologist can then review the fused images at their chosen time and annotate images to indicate potential deviations (e.g., not avoiding normal tissue or not including all tumor). The RO reviews the annotated images and decides if any changes to treatment targets are needed for the final treatment plan. Through this independent, asynchronous review of high-quality images, CORRECT overcomes many of the limitations of existing communication methods between RO-radiologist, fostering a more collaborative, efficient, and precise approach to cancer treatment planning.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVE:

To determine the feasibility of the CORRECT workflow, defined as the return of radiology feedback via CORRECT within 2 business days from receipt of initial RT targets.

SECONDARY OBJECTIVES:

I. To further assess the feasibility of the CORRECT workflow as measured by 1) time (in business days) required to install the information technology (IT) application at each practice, 2) the number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance, 3) percentage of approached patients who declined consent.

II. To assess ROs and radiologists' perceptions of acceptability, appropriateness and feasibility of the CORRECT workflow using the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM), along with the acceptability of CORRECT workflow training.

III. To identify facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial using a qualitative interview.

OUTLINE:

ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months

Tipo de estudio

Intervencionista

Inscripción (Estimado)

194

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Karen Craver
  • Número de teléfono: 336-716-0891
  • Correo electrónico: NCORP@wfusm.edu

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • PRACTICE: Must provide radiation therapy for ≥ 3 patients per month with lung cancer or head & neck cancer
  • PRACTICE: At least one radiation oncologist and one radiologist (in house, contracted, etc.) at the practice willing to participate, but may have multiple participants at the practice
  • PRACTICE: Radiation oncologist/radiologist team must use Picture Archiving and Communication System (PACS) software at this practice
  • RADIATION ONCOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIATION ONCOLOGIST (NON-PATIENT): Must treat lung and/or head & neck cancer patients with curative intent radiation therapy
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • RADIOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIOLOGIST (NON-PATIENT): Agree to review pre-treatment radiation therapy targets during the course of the study duration (approximately 12 months). Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • PATIENT: Must have any stage of clinically diagnosed lung or head & neck (HN) cancer
  • PATIENT: Planned treatment with curative intent definitive RT (with or without other treatments). Curative intent RT must be documented in the electronic medical record (EMR) by the treating radiation oncologist
  • PATIENT: Must be expected to be treated by a radiation oncologist participating in this study
  • PATIENT: Must be 18 years or older

Exclusion Criteria:

  • PRACTICE: Participation by the Community Site or Academic Community Site in another National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Cancer Care Delivery Research (CCDR) U34-supported protocol funded in NCI fiscal year 2025 or later. (Note: WF- 2301CD CONNECT is exempt from this policy, as it was funded prior to NCI fiscal year 2025.)
  • RADIATION ONCOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIATION ONCOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • RADIOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • PATIENT: Unable to understand English or Spanish
  • PATIENT: Early glottic larynx cancer planned for definitive RT alone

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Health Services Research (CORRECT workflow)

ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months.

Ancillary studies

Ancillary studies

Ancillary studies

Receive training and practice cases on CORRECT workflow

Use CORRECT workflow

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The return of radiology feedback via Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) (feasibility)
Periodo de tiempo: Within 2 business days from receipt of initial radiation therapy (RT) targets

If > 50% of patients have target feedback returned to the radiation oncologist within 2 business days, this workflow will be considered feasible in community practice.

Within 2 business days from receipt of initial radiation therapy (RT) targets

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time (in business days) required to install the information technology (IT) application
Periodo de tiempo: During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.

Will be assessed at each practice as tracked on the CORRECT IT data form

During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.
The number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance
Periodo de tiempo: During RT planning for each patient; over the 9 months of of patient accrual

Will be assessed at each practice as tracked on the CORRECT IT data form.

During RT planning for each patient; over the 9 months of of patient accrual
Percentage of approached patients who declined consent
Periodo de tiempo: During screening and enrollment over the 9 months of patient accrual

Will be assessed at each practice as tracked on the Patient Refusal form.

During screening and enrollment over the 9 months of patient accrual
Acceptability of the CORRECT workflow.
Periodo de tiempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Acceptability of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Appropriateness of the CORRECT workflow
Periodo de tiempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Intervention Appropriateness Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Feasibility of the CORRECT workflow
Periodo de tiempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Feasibility of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial
Periodo de tiempo: Up to 2 months after patient enrollment has concluded

Will be identified using qualitative interviews using the radiation oncologist/radiologist interview guide.

Up to 2 months after patient enrollment has concluded

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Kathryn Weaver, PhD, Wake Forest University Health Sciences

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

12 de diciembre de 2025

Publicado por primera vez (Actual)

15 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB00141160
  • P30CA012197 (Subvención/contrato del NIH de EE. UU.)
  • UG1CA189824 (Subvención/contrato del NIH de EE. UU.)
  • U34CA297499 (Subvención/contrato del NIH de EE. UU.)
  • NCI - 2025-07036 (Otro identificador: NCI Trial Identifier)
  • WF-2402CD (Otro identificador: CTEP Identifier)
  • WF-2402CD (Otro identificador: Lead Organization Identifier)
  • WF-2402CD (Otro identificador: DCP Identifier)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Marco de tiempo para compartir IPD

6 months after publication for a 2 year duration

Criterios de acceso compartido de IPD

upon request to NCORP@wfusm.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir